Financial Performance - The company's operating revenue for the reporting period is expected to be ¥169,713,804.31, an increase of 0.96% compared to the same period last year[6] - The total profit is expected to be ¥48,765,726.10, a decrease of 18.46% year-on-year[6] - The net profit attributable to shareholders is expected to be ¥35,180,806.67, down 15.49% from the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be ¥28,934,305.48, an increase of 2.37% year-on-year[6] - Basic earnings per share are expected to be ¥0.40, a decrease of 14.89% compared to the previous year[6] Assets and Equity - Total assets at the end of the reporting period are expected to be ¥680,477,675.69, an increase of 5.06% from the beginning of the period[6] - Shareholders' equity attributable to the company is expected to be ¥558,391,326.25, an increase of 3.56% from the beginning of the period[6] Revenue Drivers and Risks - The expected increase in operating revenue is attributed to the company's active market expansion efforts[7] - The decrease in total profit is primarily due to the absence of non-recurring gains from asset disposals in the previous year[7] - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]
新芝生物(920685) - 2025 Q4 - 年度业绩